Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

被引：7
作者：
Touzeau, Cyrille [1 ]
Perrot, Aurore [2 ]
Hulin, Cyrille [3 ]
Manier, Salomon [4 ]
Macro, Margaret [5 ]
Chretien, Marie-Lorraine [6 ]
Karlin, Lionel [7 ]
Decaux, Olivier [8 ]
Jacquet, Caroline [9 ]
Tiab, Mourad [10 ]
Leleu, Xavier [11 ]
Corre, Jill [12 ]
Jobert, Alexandra [13 ]
Planche, Lucie [14 ]
Avet-Loiseau, Herve [15 ]
Moreau, Philippe [16 ]
机构：
[1] Ctr Hosp Univ Nantes, Nantes, France
[2] CRCT, Toulouse, France
[3] Ctr Hosp Univ Bordeaux, Pessac, France
[4] Ctr Hosp Univ Hop Huriez, Lille, France
[5] Hop Cote Nacre, Caen, France
[6] CHU Dijon, Dijon, France
[7] CH Lyon Sud, Pierre Benite, France
[8] Ctr Hosp Univ Rennes Hop Pontchaillou, Rennes, France
[9] CHU Nancy, Vandoeuvre Les Nancy, France
[10] Ctr Hosp Dept, La Roche Sur Yon 9, France
[11] Serv Dhematol & Therapie Cellulaire, Poitiers, France
[12] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[13] Ctr Hosp Univ, Nantes, France
[14] CHU Nantes, Nantes, France
[15] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[16] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174044
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study
    Roussel, Murielle
    Avet-Loiseau, Herve
    Moreau, Philippe
    Huynh, Anne
    Benboubker, Lotfi
    Hulin, Cyrille
    Marit, Gerald
    Leleu, Xavier
    Pegourie, Brigitte
    Fruchart, Christophe
    Caillot, Denis
    Stoppa, Anne-Marie
    Facon, Thierry
    Harousseau, Jean-Luc
    Attal, Michel
    BLOOD, 2010, 116 (21) : 274 - 275
  • [42] EFFICACY OF CARFILZOMIB-BASED INDUCTION/CONSOLIDATION WITH OR WITHOUT AUTOLOGOUS TRANSPLANT AND LENALIDOMIDE OR CARFILZOMIB-LENALIDOMIDE MAINTENANCE IN HIGH-RISK PATIENTS IN THE FORTE TRIAL
    Mina, R.
    Belotti, A.
    Offidani, M.
    Quaresima, M.
    de Fabritiis, P.
    Patriarca, F.
    De Sabbata, G.
    Pavone, V.
    Velluti, C.
    Capra, A.
    Sgherza, N.
    Ronconi, S.
    Liberati, A. M.
    Bresciani, P.
    Cea, M.
    Spadano, A.
    Zambello, R.
    Paris, L.
    Mancuso, K.
    Musto, P.
    Boccadoro, M.
    Gay, F.
    HAEMATOLOGICA, 2021, 106 (10) : 71 - 71
  • [43] Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study
    Mina, Roberto
    Zamagni, Elena
    Rota-Scalabrini, Delia
    Corradini, Paolo
    Grasso, Mariella
    Ballanti, Stelvio
    Giuliani, Nicola
    De Rosa, Luca
    Cellini, Claudia
    Vincelli, Iolanda Donatella
    Velluti, Cristina
    Capra, Andrea
    Cafro, Anna Maria
    Gozzetti, Alessandro
    Gentile, Massimo
    Aquino, Sara
    Palmas, Angelo
    Ledda, Antonio
    Petrucci, Maria Teresa
    Musto, Pellegrino
    Boccadoro, Mario
    Gay, Francesca
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S3 - S3
  • [44] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
    Bhutani, Manisha
    Robinson, Myra
    Atrash, Shebli
    Watts, Nicole
    Paul, Barry
    Chhabra, Saurabh
    Korde, Neha
    Begic, Xhevahire
    Foureau, David M.
    Chung, David J.
    Pineda-Roman, Mauricio
    Koya, Brinda
    Varga, Cindy
    Ai, Jing
    Daniels, Natonya
    Norek, Sarah
    Sutton, Sara A.
    Anderson, Michelle B.
    Jewell, Ashley N.
    Eldridge, Paul W.
    Acampora, Donna
    Symanowski, James T.
    Costa, Luciano J.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 4393 - 4395
  • [45] Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study
    Bringhen, Sara
    Rossi, Davide
    Larocca, Alessandra
    Corradini, Paolo
    Galieni, Piero
    Malfitano, Alessandra
    Aschero, Simona
    Offidani, Massimo
    Liberati, Anna Marina
    Genuardi, Mariella
    Gaidano, Gianluca
    Palladino, Carmela
    Gentilini, Fabiana
    Boccadoro, Mario
    Sonneveld, Pieter
    Palumbo, Antonio
    BLOOD, 2015, 126 (23)
  • [46] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
    Bringhen, S.
    D'Agostino, M.
    De Paoli, L.
    Montefusco, V.
    Liberati, A. M.
    Galieni, P.
    Grammatico, S.
    Muccio, V. E.
    Esma, F.
    De Angelis, C.
    Musto, P.
    Ballanti, S.
    Offidani, M.
    Petrucci, M. T.
    Gaidano, G.
    Corradini, P.
    Palumbo, A.
    Sonneveld, P.
    Boccadoro, M.
    LEUKEMIA, 2018, 32 (04) : 979 - 985
  • [47] Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
    Bhutani, Manisha
    Robinson, Myra
    Paul, Barry
    Atrash, Shebli
    Varga, Cindy
    Begic, Xhevahire
    Foureau, David M.
    Pineda-Roman, Mauricio
    Koya, Brinda
    Norek, Sarah
    Sutton, Sara A.
    Anderson, Michelle B.
    Acampora, Donna
    Symanowski, James T.
    Voorhees, Peter M.
    Usmani, Saad
    BLOOD, 2022, 140 : 4440 - 4441
  • [48] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
    S Bringhen
    M D'Agostino
    L De Paoli
    V Montefusco
    A M Liberati
    P Galieni
    S Grammatico
    V E Muccio
    F Esma
    C De Angelis
    P Musto
    S Ballanti
    M Offidani
    M T Petrucci
    G Gaidano
    P Corradini
    A Palumbo
    P Sonneveld
    M Boccadoro
    Leukemia, 2018, 32 : 979 - 985
  • [49] A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Parmar, Harsh
    Phull, Pooja
    Doucette, Kimberly
    Feinman, Rena
    Zenreich, Joshua
    Anand, Palka
    Ivanovski, Kristin
    Pace, Monique
    Biamonte, Lisa
    Campanaro, Martha
    McClendon, Trina
    Limbad, Chandani
    BaboolallAracena, Samanta
    Aleman, Adolfo
    Unawane, Rashmi
    Pendergrass, Elizabeth
    Layton, Marie
    Breeze, Genevieve
    Chappell, Aimee
    Della Pia, Alexandra
    Kumka, Susan
    Siegel, David S.
    BLOOD, 2023, 142
  • [50] Phase 3 randomized study of Daratumumab plus lenalidomide and Dexamethasone (D-Rd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)
    Weisel, K.
    Facon, T.
    Kumar, S.
    Plesner, T.
    Orlowski, R. Z.
    Moreau, P.
    Bahlis, N.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Mace, J. R.
    Ahmadi, T.
    Chiu, C.
    Wang, J.
    van Rampelbergh, R.
    Uhlar, C. M.
    Kobos, R.
    Qi, M.
    Usmani, S. Z.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 194 - 194
12345